Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...

A human ear attached to a woman’s foot sounds like a stunt from a horror film, yet it is the centerpiece of a real, carefully planned medical rescue. In a world first, surgeons in China temporarily ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of im ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improv ...

A woman's body has been found to consist of varying proportions of male and female cells because of an extremely rare form of ...

Samrica Zogar faced a challenging upbringing in Liberia because of her limb differences. In an exclusive interview with ...

Bored Panda has curated a list of people with rare physical traits that might make you do a double take. From extra or ...